- Update: Spot Bio launches with $40M to study non-viral gene therapy for muscular dystrophyA startup with operations in California and China has quietly begun tests of a genetic medicine that could restore dystrophin, the vital muscle protein that is broken or missing in people born with…Endpoints · 1mo ago↗ source
- Triveni Bio raises $65M ahead of upcoming readouts on eczema drugsTriveni Bio announced a $65 million Series C after its second asset for eczema entered clinical studies last month. The Series C was co-led by Ascenta Capital and Janus Henderson Investors and in…Endpoints · 1mo ago↗ source
- Migraine biotech Vedana Therapeutics makes its debut with $46M Series AVedana Therapeutics has emerged from stealth with $46 million in Series A proceeds with the goal of developing treatments that could free patients from migraines entirely. Available treatments fo…